ES2626820T3 - Moduladores selectivos del receptor de andrógenos - Google Patents
Moduladores selectivos del receptor de andrógenos Download PDFInfo
- Publication number
- ES2626820T3 ES2626820T3 ES12775406.7T ES12775406T ES2626820T3 ES 2626820 T3 ES2626820 T3 ES 2626820T3 ES 12775406 T ES12775406 T ES 12775406T ES 2626820 T3 ES2626820 T3 ES 2626820T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- amino
- mmol
- benzonitrile
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 194
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 96
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- CXFSVKGROITHRY-TZMCWYRMSA-N 2-chloro-4-[[(1r,2r)-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@@](O)(C)CCC1 CXFSVKGROITHRY-TZMCWYRMSA-N 0.000 claims description 20
- 201000000585 muscular atrophy Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 12
- 229910016523 CuKa Inorganic materials 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- CXFSVKGROITHRY-GXTWGEPZSA-N 2-chloro-4-[[(1s,2r)-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@@H]1[C@@](O)(C)CCC1 CXFSVKGROITHRY-GXTWGEPZSA-N 0.000 claims description 3
- 229940100611 topical cream Drugs 0.000 claims description 2
- 229940042129 topical gel Drugs 0.000 claims description 2
- 229940041677 topical spray Drugs 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- 238000006243 chemical reaction Methods 0.000 description 79
- 239000000203 mixture Substances 0.000 description 77
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 65
- 238000002360 preparation method Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 55
- 235000019439 ethyl acetate Nutrition 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 238000000034 method Methods 0.000 description 50
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 239000007787 solid Substances 0.000 description 37
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 239000000463 material Substances 0.000 description 27
- 239000003921 oil Substances 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 23
- 229910052938 sodium sulfate Inorganic materials 0.000 description 23
- 235000011152 sodium sulphate Nutrition 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- -1 racemates Chemical class 0.000 description 22
- 239000012043 crude product Substances 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- 210000003205 muscle Anatomy 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 17
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000002265 prevention Effects 0.000 description 17
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000009739 binding Methods 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- 239000005909 Kieselgur Substances 0.000 description 14
- 150000001414 amino alcohols Chemical class 0.000 description 14
- 239000003098 androgen Substances 0.000 description 14
- 150000002118 epoxides Chemical class 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- IOKBJSAKTZEMBR-UHFFFAOYSA-N 2-chloro-4-fluoro-3-methylbenzonitrile Chemical compound CC1=C(F)C=CC(C#N)=C1Cl IOKBJSAKTZEMBR-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 description 12
- 238000005984 hydrogenation reaction Methods 0.000 description 12
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 239000001569 carbon dioxide Substances 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 210000002307 prostate Anatomy 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 150000001540 azides Chemical class 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000012442 inert solvent Substances 0.000 description 9
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 8
- 206010006895 Cachexia Diseases 0.000 description 8
- 241000282553 Macaca Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 208000020431 spinal cord injury Diseases 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 206010058359 Hypogonadism Diseases 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- LTFMOMPVVZUGDS-UHFFFAOYSA-N 2-chloro-3-ethyl-4-fluorobenzonitrile Chemical compound CCC1=C(F)C=CC(C#N)=C1Cl LTFMOMPVVZUGDS-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 description 6
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940030486 androgens Drugs 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 235000010290 biphenyl Nutrition 0.000 description 6
- 125000006267 biphenyl group Chemical group 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 5
- 206010020100 Hip fracture Diseases 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000011540 hip replacement Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000013150 knee replacement Methods 0.000 description 5
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 5
- 229910052808 lithium carbonate Inorganic materials 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 230000003637 steroidlike Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 4
- HUJPNEOHGRUPJE-UHFFFAOYSA-N 2-chloro-3-ethyl-4-[(3-hydroxy-3-methyloxan-4-yl)amino]benzonitrile Chemical compound CCC1=C(Cl)C(C#N)=CC=C1NC1C(O)(C)COCC1 HUJPNEOHGRUPJE-UHFFFAOYSA-N 0.000 description 4
- 102100032187 Androgen receptor Human genes 0.000 description 4
- 241000723377 Coffea Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000005708 Sodium hypochlorite Substances 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 238000009167 androgen deprivation therapy Methods 0.000 description 4
- 108010080146 androgen receptors Proteins 0.000 description 4
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical compound ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000016213 coffee Nutrition 0.000 description 4
- 235000013353 coffee beverage Nutrition 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 4
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 4
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000012286 potassium permanganate Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 102000005969 steroid hormone receptors Human genes 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- KKBCPZUWBKCECT-UHFFFAOYSA-N 2-amino-1-methylcyclopentan-1-ol Chemical compound CC1(O)CCCC1N KKBCPZUWBKCECT-UHFFFAOYSA-N 0.000 description 3
- PGKPNNMOFHNZJX-UHFFFAOYSA-N 2-chloro-4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C(Cl)=C1 PGKPNNMOFHNZJX-UHFFFAOYSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 3
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000011560 quantum fluid Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- GNLJBJNONOOOQC-UHFFFAOYSA-N $l^{3}-carbane;magnesium Chemical compound [Mg]C GNLJBJNONOOOQC-UHFFFAOYSA-N 0.000 description 2
- WMUUFFALJVSVRI-VQTJNVASSA-N (1r,2s)-2-(dibenzylamino)-1-methylcyclopentan-1-ol Chemical compound C[C@@]1(O)CCC[C@@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 WMUUFFALJVSVRI-VQTJNVASSA-N 0.000 description 2
- KKBCPZUWBKCECT-NTSWFWBYSA-N (1r,2s)-2-amino-1-methylcyclopentan-1-ol Chemical compound C[C@@]1(O)CCC[C@@H]1N KKBCPZUWBKCECT-NTSWFWBYSA-N 0.000 description 2
- JFFOUICIRBXFRC-CRCLSJGQSA-N (1r,2s)-2-aminocyclopentan-1-ol Chemical compound N[C@H]1CCC[C@H]1O JFFOUICIRBXFRC-CRCLSJGQSA-N 0.000 description 2
- KKBCPZUWBKCECT-WDSKDSINSA-N (1s,2s)-2-amino-1-methylcyclopentan-1-ol Chemical compound C[C@]1(O)CCC[C@@H]1N KKBCPZUWBKCECT-WDSKDSINSA-N 0.000 description 2
- PBQHDTRHGNGTLZ-RFZPGFLSSA-N (3s,4r)-4-aminooxan-3-ol Chemical compound N[C@@H]1CCOC[C@H]1O PBQHDTRHGNGTLZ-RFZPGFLSSA-N 0.000 description 2
- OPJACWGLWDZDTR-RFZPGFLSSA-N (3s,4r)-4-azidooxan-3-ol Chemical compound O[C@@H]1COCC[C@H]1N=[N+]=[N-] OPJACWGLWDZDTR-RFZPGFLSSA-N 0.000 description 2
- FAHKAHMLFQVMPR-QWWZWVQMSA-N (3s,4r)-4-azidooxolan-3-ol Chemical compound O[C@@H]1COC[C@H]1N=[N+]=[N-] FAHKAHMLFQVMPR-QWWZWVQMSA-N 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- XMDQJXIEKHMDMG-UHFFFAOYSA-N 1-methyl-6-oxabicyclo[3.1.0]hexane Chemical compound C1CCC2OC21C XMDQJXIEKHMDMG-UHFFFAOYSA-N 0.000 description 2
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 2
- ZSBWUNDRDHVNJL-UHFFFAOYSA-N 2-Methyl-2-cyclopenten-1-one Chemical compound CC1=CCCC1=O ZSBWUNDRDHVNJL-UHFFFAOYSA-N 0.000 description 2
- TWZWYKFAVZDTPH-UHFFFAOYSA-N 2-amino-1-methylcyclohexan-1-ol;hydrochloride Chemical compound Cl.CC1(O)CCCCC1N TWZWYKFAVZDTPH-UHFFFAOYSA-N 0.000 description 2
- QLJHZJMTNNEHSD-UHFFFAOYSA-N 2-amino-1-methylcyclopentan-1-ol;hydrochloride Chemical compound Cl.CC1(O)CCCC1N QLJHZJMTNNEHSD-UHFFFAOYSA-N 0.000 description 2
- BRAQUKHJATYJAD-UHFFFAOYSA-N 2-chloro-3-methyl-4-[(3-oxooxan-4-yl)amino]benzonitrile Chemical compound CC1=C(Cl)C(C#N)=CC=C1NC1C(=O)COCC1 BRAQUKHJATYJAD-UHFFFAOYSA-N 0.000 description 2
- UXFCOCQGVQXIEJ-UHFFFAOYSA-N 2-chloro-4-[(3-hydroxy-3-methyloxan-4-yl)amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1NC1C(O)(C)COCC1 UXFCOCQGVQXIEJ-UHFFFAOYSA-N 0.000 description 2
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- NWPNXBQSRGKSJB-UHFFFAOYSA-N 2-methylbenzonitrile Chemical compound CC1=CC=CC=C1C#N NWPNXBQSRGKSJB-UHFFFAOYSA-N 0.000 description 2
- TXPJSTNMZHBTRF-UHFFFAOYSA-N 2-methylcyclopent-2-en-1-ol Chemical compound CC1=CCCC1O TXPJSTNMZHBTRF-UHFFFAOYSA-N 0.000 description 2
- MUGSKSNNEORSJG-UHFFFAOYSA-N 3174-74-1 Chemical compound C1CC=CCO1 MUGSKSNNEORSJG-UHFFFAOYSA-N 0.000 description 2
- XGDSKVZBNGTARC-UHFFFAOYSA-N 4,7-dioxabicyclo[4.1.0]heptane Chemical compound C1OCCC2OC21 XGDSKVZBNGTARC-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 102100025803 Progesterone receptor Human genes 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- UAVMYEWWABQPFX-YUMQZZPRSA-N [(1s,2s)-2-azidocyclopentyl]oxy-trimethylsilane Chemical compound C[Si](C)(C)O[C@H]1CCC[C@@H]1N=[N+]=[N-] UAVMYEWWABQPFX-YUMQZZPRSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960000226 edetol Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 108020003113 steroid hormone receptors Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- YPCCJSNMIHLMOS-UHFFFAOYSA-N tert-butyl n-(4-oxooxolan-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1COCC1=O YPCCJSNMIHLMOS-UHFFFAOYSA-N 0.000 description 2
- SFIADDJLFYFDGK-RNFRBKRXSA-N tert-butyl n-[(3r,4s)-4-hydroxyoxolan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1COC[C@H]1O SFIADDJLFYFDGK-RNFRBKRXSA-N 0.000 description 2
- FRYVGAWPICGABU-UHFFFAOYSA-N tert-butyl-(2-methylcyclopent-2-en-1-yl)oxy-diphenylsilane Chemical compound CC1=CCCC1O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 FRYVGAWPICGABU-UHFFFAOYSA-N 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- TWPKIBFRKXFXRJ-UHFFFAOYSA-N (1-bromo-2-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(Br)CC1=CC=CC=C1 TWPKIBFRKXFXRJ-UHFFFAOYSA-N 0.000 description 1
- ZFSXKSSWYSZPGQ-TYSVMGFPSA-N (1r,2r)-2-aminocyclopentan-1-ol;hydrochloride Chemical compound Cl.N[C@@H]1CCC[C@H]1O ZFSXKSSWYSZPGQ-TYSVMGFPSA-N 0.000 description 1
- XCIJQGOMBGCEDC-RBUKOAKNSA-N (1r,2s)-2-(dibenzylamino)cyclopentan-1-ol Chemical compound O[C@@H]1CCC[C@@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 XCIJQGOMBGCEDC-RBUKOAKNSA-N 0.000 description 1
- HIUMGKLRRQVUEG-SFHVURJKSA-N (2s)-2-(dibenzylamino)cyclopentan-1-one Chemical compound O=C1CCC[C@@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 HIUMGKLRRQVUEG-SFHVURJKSA-N 0.000 description 1
- KKBCPZUWBKCECT-ZBHICJROSA-N (2s)-2-amino-1-methylcyclopentan-1-ol Chemical compound CC1(O)CCC[C@@H]1N KKBCPZUWBKCECT-ZBHICJROSA-N 0.000 description 1
- QLJHZJMTNNEHSD-GNVLWMSISA-N (2s)-2-amino-1-methylcyclopentan-1-ol;hydrochloride Chemical compound Cl.CC1(O)CCC[C@@H]1N QLJHZJMTNNEHSD-GNVLWMSISA-N 0.000 description 1
- NCRDJMVTAMAHSE-BDAKNGLRSA-N (3r,4r)-4-[tert-butyl(dimethyl)silyl]oxyoxolan-3-amine Chemical compound CC(C)(C)[Si](C)(C)O[C@H]1COC[C@H]1N NCRDJMVTAMAHSE-BDAKNGLRSA-N 0.000 description 1
- LAVSHMRTPGFJLY-RNFRBKRXSA-N (3r,4s)-4-trimethylsilyloxyoxolan-3-amine Chemical compound C[Si](C)(C)O[C@@H]1COC[C@H]1N LAVSHMRTPGFJLY-RNFRBKRXSA-N 0.000 description 1
- LAVSHMRTPGFJLY-BQBZGAKWSA-N (3s,4r)-4-trimethylsilyloxyoxolan-3-amine Chemical compound C[Si](C)(C)O[C@H]1COC[C@@H]1N LAVSHMRTPGFJLY-BQBZGAKWSA-N 0.000 description 1
- SSYDTHANSGMJTP-IMJSIDKUSA-N (3s,4s)-oxolane-3,4-diol Chemical compound O[C@H]1COC[C@@H]1O SSYDTHANSGMJTP-IMJSIDKUSA-N 0.000 description 1
- PVBLJPCMWKGTOH-UHFFFAOYSA-N 1-aminocyclohexan-1-ol Chemical compound NC1(O)CCCCC1 PVBLJPCMWKGTOH-UHFFFAOYSA-N 0.000 description 1
- ATQUFXWBVZUTKO-UHFFFAOYSA-N 1-methylcyclopentene Chemical compound CC1=CCCC1 ATQUFXWBVZUTKO-UHFFFAOYSA-N 0.000 description 1
- FDJKLIVKKYFLSA-UHFFFAOYSA-N 1-oxido-1-azoniabicyclo[2.2.2]octane Chemical compound C1CC2CC[N+]1([O-])CC2 FDJKLIVKKYFLSA-UHFFFAOYSA-N 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- NYOWYNSNCXRVNQ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indazole Chemical class C1=CCC2CNNC2=C1 NYOWYNSNCXRVNQ-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- MFJCOJWVBRSPNQ-SNVBAGLBSA-N 2-chloro-3-methyl-4-[[(3r)-4-oxooxolan-3-yl]amino]benzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1C(=O)COC1 MFJCOJWVBRSPNQ-SNVBAGLBSA-N 0.000 description 1
- MFJCOJWVBRSPNQ-JTQLQIEISA-N 2-chloro-3-methyl-4-[[(3s)-4-oxooxolan-3-yl]amino]benzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@@H]1C(=O)COC1 MFJCOJWVBRSPNQ-JTQLQIEISA-N 0.000 description 1
- CXFSVKGROITHRY-UHFFFAOYSA-N 2-chloro-4-[(2-hydroxy-2-methylcyclopentyl)amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1NC1C(O)(C)CCC1 CXFSVKGROITHRY-UHFFFAOYSA-N 0.000 description 1
- LRQSPCAZHXKTHC-HIFRSBDPSA-N 2-chloro-4-[[(1r,2s)-2-hydroxy-2-methylcyclohexyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@](O)(C)CCCC1 LRQSPCAZHXKTHC-HIFRSBDPSA-N 0.000 description 1
- CXFSVKGROITHRY-OCCSQVGLSA-N 2-chloro-4-[[(1r,2s)-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@](O)(C)CCC1 CXFSVKGROITHRY-OCCSQVGLSA-N 0.000 description 1
- YPTVQJWGIHXOLP-OLZOCXBDSA-N 2-chloro-4-[[(1r,2s)-2-hydroxycyclohexyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@@H](O)CCCC1 YPTVQJWGIHXOLP-OLZOCXBDSA-N 0.000 description 1
- VQJACGXPDSHWKM-BZPMIXESSA-N 2-chloro-4-[[(1r,2s,3r)-2,3-dihydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@@](O)(C)[C@H](O)CC1 VQJACGXPDSHWKM-BZPMIXESSA-N 0.000 description 1
- LRQSPCAZHXKTHC-DZGCQCFKSA-N 2-chloro-4-[[(1s,2r)-2-hydroxy-2-methylcyclohexyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@@H]1[C@@](O)(C)CCCC1 LRQSPCAZHXKTHC-DZGCQCFKSA-N 0.000 description 1
- YPTVQJWGIHXOLP-QWHCGFSZSA-N 2-chloro-4-[[(1s,2r)-2-hydroxycyclohexyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@@H]1[C@H](O)CCCC1 YPTVQJWGIHXOLP-QWHCGFSZSA-N 0.000 description 1
- VQJACGXPDSHWKM-SGMGOOAPSA-N 2-chloro-4-[[(1s,2r,3s)-2,3-dihydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@@H]1[C@](O)(C)[C@@H](O)CC1 VQJACGXPDSHWKM-SGMGOOAPSA-N 0.000 description 1
- SNHUIUFMXNZBIZ-YPMHNXCESA-N 2-chloro-4-[[(3r,4r)-4-hydroxy-4-methyloxolan-3-yl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@](O)(C)COC1 SNHUIUFMXNZBIZ-YPMHNXCESA-N 0.000 description 1
- KKZGPJBJCNNFFY-MNOVXSKESA-N 2-chloro-4-[[(3r,4r)-4-hydroxyoxolan-3-yl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@@H](O)COC1 KKZGPJBJCNNFFY-MNOVXSKESA-N 0.000 description 1
- SNHUIUFMXNZBIZ-DGCLKSJQSA-N 2-chloro-4-[[(3r,4s)-4-hydroxy-4-methyloxolan-3-yl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@H]1[C@@](O)(C)COC1 SNHUIUFMXNZBIZ-DGCLKSJQSA-N 0.000 description 1
- SNHUIUFMXNZBIZ-WCQYABFASA-N 2-chloro-4-[[(3s,4s)-4-hydroxy-4-methyloxolan-3-yl]amino]-3-methylbenzonitrile Chemical compound C1=CC(C#N)=C(Cl)C(C)=C1N[C@@H]1[C@@](O)(C)COC1 SNHUIUFMXNZBIZ-WCQYABFASA-N 0.000 description 1
- LONAYYKXZPCZNH-UHFFFAOYSA-N 2-methylcyclohex-2-en-1-ol Chemical compound CC1=CCCCC1O LONAYYKXZPCZNH-UHFFFAOYSA-N 0.000 description 1
- AIUTZIYTEUMXGG-UHFFFAOYSA-N 3,6-dioxabicyclo[3.1.0]hexane Chemical compound C1OCC2OC12 AIUTZIYTEUMXGG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- IVBVKTPDEWDNRW-UHFFFAOYSA-N 4-bromooxane Chemical compound BrC1CCOCC1 IVBVKTPDEWDNRW-UHFFFAOYSA-N 0.000 description 1
- ZHZKXFPBIRNQFW-UHFFFAOYSA-N 5-chloro-1-methylcyclopentene Chemical compound CC1=CCCC1Cl ZHZKXFPBIRNQFW-UHFFFAOYSA-N 0.000 description 1
- FBVZZXGFPMYONR-UHFFFAOYSA-N 7a-methyl-3,3a,4,5,6,7-hexahydro-1,3-benzoxazol-2-one Chemical compound C1CCCC2NC(=O)OC21C FBVZZXGFPMYONR-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 1
- 101100330193 Homo sapiens CYREN gene Proteins 0.000 description 1
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910013627 M-Si Inorganic materials 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- JYDBMEALPZGOSP-BQBZGAKWSA-N [(3r,4s)-4-azidooxolan-3-yl]oxy-trimethylsilane Chemical compound C[Si](C)(C)O[C@H]1COC[C@@H]1N=[N+]=[N-] JYDBMEALPZGOSP-BQBZGAKWSA-N 0.000 description 1
- JYDBMEALPZGOSP-RNFRBKRXSA-N [(3s,4r)-4-azidooxolan-3-yl]oxy-trimethylsilane Chemical compound C[Si](C)(C)O[C@@H]1COC[C@H]1N=[N+]=[N-] JYDBMEALPZGOSP-RNFRBKRXSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- QBULTKZGKKTANH-UHFFFAOYSA-M chloro(dimethyl)sulfanium;chloride Chemical compound [Cl-].C[S+](C)Cl QBULTKZGKKTANH-UHFFFAOYSA-M 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 201000003585 eunuchism Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000046818 human AR Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000037106 male hypogonadism Diseases 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- WZBCIFZVBDLSDN-UHFFFAOYSA-N n-benzyl-1-phenylmethanamine;hydrobromide Chemical compound Br.C=1C=CC=CC=1CNCC1=CC=CC=C1 WZBCIFZVBDLSDN-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- HRYZDCXUBCWVHU-RZUBCFFCSA-N tert-butyl-[[(1r,2s,5r)-1-methyl-6-oxabicyclo[3.1.0]hexan-2-yl]oxy]-diphenylsilane Chemical compound O([C@@H]1[C@@]2(O[C@@H]2CC1)C)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 HRYZDCXUBCWVHU-RZUBCFFCSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546711P | 2011-10-13 | 2011-10-13 | |
| US201161546711P | 2011-10-13 | ||
| PCT/US2012/058824 WO2013055577A1 (en) | 2011-10-13 | 2012-10-05 | Selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2626820T3 true ES2626820T3 (es) | 2017-07-26 |
Family
ID=47046879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12775406.7T Active ES2626820T3 (es) | 2011-10-13 | 2012-10-05 | Moduladores selectivos del receptor de andrógenos |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8658693B2 (enExample) |
| EP (1) | EP2766350B1 (enExample) |
| JP (1) | JP6002228B2 (enExample) |
| KR (1) | KR20140067102A (enExample) |
| CN (1) | CN103842348B (enExample) |
| AP (1) | AP2014007548A0 (enExample) |
| AR (1) | AR088082A1 (enExample) |
| AU (1) | AU2012321113B2 (enExample) |
| BR (1) | BR112014008668A2 (enExample) |
| CA (1) | CA2847889A1 (enExample) |
| CL (1) | CL2014000895A1 (enExample) |
| CO (1) | CO6910195A2 (enExample) |
| CR (1) | CR20140156A (enExample) |
| DO (1) | DOP2014000075A (enExample) |
| EA (1) | EA201490519A1 (enExample) |
| EC (1) | ECSP14013305A (enExample) |
| ES (1) | ES2626820T3 (enExample) |
| GT (1) | GT201400067A (enExample) |
| IL (1) | IL231440A0 (enExample) |
| MX (1) | MX2014004558A (enExample) |
| PE (1) | PE20141669A1 (enExample) |
| PH (1) | PH12014500808A1 (enExample) |
| PL (1) | PL2766350T3 (enExample) |
| PT (1) | PT2766350T (enExample) |
| SG (1) | SG11201401794YA (enExample) |
| TN (1) | TN2014000136A1 (enExample) |
| TW (1) | TWI449686B (enExample) |
| WO (1) | WO2013055577A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| ES2693520T3 (es) | 2013-12-04 | 2018-12-12 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| EP3140300B1 (en) | 2014-05-07 | 2019-08-14 | Evotec International GmbH | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| ES2876411T3 (es) | 2016-08-15 | 2021-11-12 | Pfizer | Inhibidores de piridopirimdinona CDK2/4/6 |
| ES2824495T3 (es) | 2016-09-02 | 2021-05-12 | Suven Life Sciences Ltd | Moduladores alostéricos positivos del receptor muscarínico M1 |
| US11076596B2 (en) | 2017-09-18 | 2021-08-03 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| EP4171568B1 (en) * | 2020-06-24 | 2025-08-27 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| WO2025104624A1 (en) * | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3594405A (en) * | 1968-05-17 | 1971-07-20 | Du Pont | Substituted pyranyl anilines as plant growth modifiers |
| EP1256578B1 (en) * | 2001-05-11 | 2006-01-11 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| WO2006124447A2 (en) * | 2005-05-13 | 2006-11-23 | Eli Lilly And Company | Substituted n-arylpyrrolidines as selective androgen receptor modulators |
| AU2006319916A1 (en) * | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
| JP2010524950A (ja) * | 2007-04-16 | 2010-07-22 | セレネックス， インコーポレイテッド | テトラヒドロインドールおよびテトラヒドロインダゾール誘導体 |
| CA2702777A1 (en) * | 2007-10-19 | 2009-04-23 | Michelle Letendre-Hedlund | Methods of identifying environmentally friendly businesses or individuals |
| MX2010009162A (es) * | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
-
2012
- 2012-09-27 AR ARP120103597A patent/AR088082A1/es unknown
- 2012-09-28 TW TW101136038A patent/TWI449686B/zh not_active IP Right Cessation
- 2012-10-05 CN CN201280049445.8A patent/CN103842348B/zh active Active
- 2012-10-05 EP EP12775406.7A patent/EP2766350B1/en active Active
- 2012-10-05 AU AU2012321113A patent/AU2012321113B2/en not_active Ceased
- 2012-10-05 PT PT127754067T patent/PT2766350T/pt unknown
- 2012-10-05 SG SG11201401794YA patent/SG11201401794YA/en unknown
- 2012-10-05 PL PL12775406T patent/PL2766350T3/pl unknown
- 2012-10-05 ES ES12775406.7T patent/ES2626820T3/es active Active
- 2012-10-05 JP JP2014535757A patent/JP6002228B2/ja active Active
- 2012-10-05 US US13/645,535 patent/US8658693B2/en active Active
- 2012-10-05 KR KR1020147009338A patent/KR20140067102A/ko not_active Abandoned
- 2012-10-05 AP AP2014007548A patent/AP2014007548A0/xx unknown
- 2012-10-05 EA EA201490519A patent/EA201490519A1/ru unknown
- 2012-10-05 CA CA2847889A patent/CA2847889A1/en not_active Abandoned
- 2012-10-05 PH PH1/2014/500808A patent/PH12014500808A1/en unknown
- 2012-10-05 BR BR112014008668A patent/BR112014008668A2/pt not_active IP Right Cessation
- 2012-10-05 WO PCT/US2012/058824 patent/WO2013055577A1/en not_active Ceased
- 2012-10-05 MX MX2014004558A patent/MX2014004558A/es not_active Application Discontinuation
- 2012-10-05 PE PE2014000521A patent/PE20141669A1/es not_active Application Discontinuation
-
2014
- 2014-03-10 IL IL231440A patent/IL231440A0/en unknown
- 2014-03-17 CO CO14057028A patent/CO6910195A2/es unknown
- 2014-03-28 TN TNP2014000136A patent/TN2014000136A1/en unknown
- 2014-04-04 CR CR20140156A patent/CR20140156A/es unknown
- 2014-04-10 CL CL2014000895A patent/CL2014000895A1/es unknown
- 2014-04-11 EC ECSP14013305 patent/ECSP14013305A/es unknown
- 2014-04-11 DO DO2014000075A patent/DOP2014000075A/es unknown
- 2014-04-11 GT GT201400067A patent/GT201400067A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2626820T3 (es) | Moduladores selectivos del receptor de andrógenos | |
| CN112135812B (zh) | 氯胺酮衍生物及其药物组合物 | |
| ES2715458T3 (es) | Inhibidores de dihidropirrolopiridina de ROR-gamma | |
| TW200924746A (en) | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use | |
| HK1198165A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| WO2013192097A1 (en) | Preparation, uses and solid forms of obeticholic acid | |
| PT85379B (pt) | Processo para a preparacao de derivados de amida e de composicoes farmaceuticas que os contem | |
| EP2802320B1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| US10266529B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| ES2822830T3 (es) | Antagonistas selectivos de NR2B | |
| CN104470911B (zh) | 氨基甲酸酯/脲衍生物 | |
| WO2017111979A1 (en) | Polymorphic crystalline forms of obeticholic acid | |
| DK2762466T3 (en) | phenyl derivative | |
| ES2821407T3 (es) | Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos | |
| US20220098152A1 (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| EP2066677B1 (en) | Pyridooxazepine progesteron receptor modulators | |
| EP4324835A1 (en) | Pyrimidinone derivative and preparation method therefor, pharmaceutical composition, and use | |
| JPH01311060A (ja) | ３，４‐ジヒドロキシ‐２‐ピロリジノン誘導体およびそれらの製造法 | |
| EA023970B1 (ru) | Производные пиразолина и их применение в качестве селективных модуляторов рецептора андрогена | |
| ES2999070T3 (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| US12448347B2 (en) | Polymorphic forms of (R)-oxybutynin hydrochloride | |
| TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
| HK40038018B (en) | Ketamine derivatives and pharmaceutical compositions thereof | |
| HK40038018A (en) | Ketamine derivatives and pharmaceutical compositions thereof | |
| FR2992645A1 (fr) | Nouveaux derives de pyrrolidine |